A 2015 landmark study in Science identified rs2305957 — a variant on chromosome 4 within a low-recombination haplotype block spanning several genes including HSPA4L and PLK4 — as a maternal genetic risk factor for mitotic-origin embryo aneuploidy¹¹ mitotic-origin embryo aneuploidy
chromosome copy-number errors arising from cell-division mistakes after fertilisation, as distinct from meiotic aneuploidy arising during egg or sperm formation. The A allele of rs2305957 was associated with an odds ratio of 1.244 for embryo mitotic aneuploidy (P=8.68×10⁻¹⁶) across 2,362 mothers and 20,798 preimplantation embryos, replicated independently in both European and East Asian ancestry subgroups. The same variant has since been linked to reduced blastocyst formation rates and early recurrent miscarriage in Chinese Han women undergoing IVF.

The Mechanism

The associated region spans over 600 kilobases of chromosome 4q28 and contains multiple genes. PLK4²² PLK4
Polo-like kinase 4, the master regulator of centriole duplication and therefore of spindle pole number during cell division is the primary functional candidate: both overexpression and underexpression of PLK4 can trigger chromosome instability through multipolar spindle formation. A subsequent study demonstrated that the A allele haplotype is specifically enriched in embryos undergoing tripolar mitosis³³ tripolar mitosis
cell division into three daughter cells instead of two, generating complex multi-chromosome aneuploidies incompatible with development, explaining why AA-genotype mothers contribute fewer viable blastocysts for IVF biopsy. The association is strictly maternal — paternal genotype at this locus showed no significant effect on embryo aneuploidy rates.

The variant is physically located within an intron of HSPA4L (Heat Shock Protein Family A Member 4-Like), which is independently relevant to male reproductive biology. HSPA4L belongs to the HSP110 family and is the most highly expressed gene in testis among broadly expressed heat-shock proteins (101.7 nTPM, Human Protein Atlas), with peak expression in pachytene spermatocytes and round and elongating spermatids⁴⁴ pachytene spermatocytes and round and elongating spermatids
the cells undergoing and completing meiosis. Male mice lacking Hspa4l show a ~42% infertility rate, reduced sperm count and motility, and excess germ-cell apoptosis within seminiferous tubules ⁵⁵ Held et al. 2006, Mol Cell Biol. In human studies, decreased HSPA4L protein in spermatozoa correlates with asthenozoospermia and poor sperm-oocyte penetration ⁶⁶ Liu et al. 2019, Mol Reprod Dev. Whether rs2305957 modulates HSPA4L expression in human testicular tissue via eQTL effects has not been formally established, so the male fertility relevance of this specific intronic variant remains an open question.

The Evidence

The original discovery by McCoy et al. 2015 (Science)⁷⁷ McCoy et al. 2015 (Science)
Common variants spanning PLK4 are associated with mitotic-origin aneuploidy in human embryos is among the most statistically robust GWAS findings in reproductive genetics: a discovery cohort of 2,362 mothers contributing 20,798 blastomere biopsies, validated in a separate cohort of 34 mothers and 283 embryos. The minor A allele displayed a dose-dependent effect: aneuploidy prevalence was 24.6% (GG), 27.0% (AG), and 31.7% (AA) for paternal- chromosome aneuploidies. The association was absent from Neanderthal and Denisovan genomes, suggesting the risk variant arose recently in modern humans and may have hitchhiked to intermediate frequency during a selective sweep.

A Chinese Han cohort study (Zhang et al. 2017, Fertil Steril)⁸⁸ Chinese Han cohort study (Zhang et al. 2017, Fertil Steril)
Maternal common variant rs2305957 spanning PLK4 is associated with blastocyst formation and early recurrent miscarriage enrolled 2,015 IVF patients, 530 early recurrent miscarriage (ERM) cases, and 600 fertile controls. AA-genotype women showed the lowest blastocyst formation rate among IVF patients, and the A allele was significantly associated with ERM under both additive and dominant models, though no differences in implantation rate, early miscarriage rate, or live birth rate were observed in the IVF cohort itself.

However, a Japanese case-control study (Yoshihara et al. 2020)⁹⁹ Japanese case-control study (Yoshihara et al. 2020)
PLK4 and STAG3 are not associated with recurrent pregnancy loss caused by embryonic aneuploidy of 184 RPL cases with aneuploid products of conception and 190 fertile controls found no significant association, providing a negative replication for the RPL endpoint specifically. A further study in the International Journal of Research in Medical Sciences also reported no association of rs2305957 with recurrent pregnancy loss.

The cumulative evidence supports a genuine association with embryo aneuploidy at a population scale, particularly in IVF contexts where it may affect embryo viability and blastocyst yield, but the clinical significance for recurrent pregnancy loss in the general population remains unresolved.

Practical Actions

For women: The A allele (particularly AA genotype) may be associated with a modestly higher rate of embryo aneuploidy during IVF cycles, potentially manifesting as a lower proportion of euploid blastocysts available for transfer. This does not translate to certainty of failed pregnancy — many AA-genotype women conceive without difficulty — but it is a factor that reproductive specialists may consider when counselling on expected embryo yields and the potential benefit of preimplantation genetic testing. No dietary supplement or intervention is known to modify centriole fidelity or PLK4 function.

For men: HSPA4L protein levels in sperm may be a useful functional readout in the context of asthenozoospermia, though no intervention targeting HSPA4L expression is currently available. Men with this variant who show sperm motility problems should prioritise clinical andrological evaluation.

Interactions

The functional biology of PLK4 is essentially maternal in the context of this variant — the original GWAS detected no paternal genotype association with embryo aneuploidy, implying the effect operates through maternal spindle regulation in the early embryo rather than paternal sperm contribution.

For male fertility specifically, HSPA4L function is closely intertwined with the broader heat-shock chaperone network in spermatogenesis, which includes HSPA4 and HSPA1L. Double knockout of Hspa4l and Hspa4 in mice causes neonatal lethality, while single knockouts each show male fertility defects, suggesting the two paralogs have partially redundant roles in spermatocyte and spermatid viability.

Compound action proposal (for supervisor review): SOX5 rs2305957 + DNAH10 rs12032124: the original assignment proposed a dual male fertility compound action for these two SNPs. Based on the research completed here, rs2305957 (HSPA4L/PLK4 region) has limited direct evidence for male fertility effects at the SNP level (the HSPA4L knockout mouse data and human sperm protein data are gene-level, not variant-level). rs12032124 (DNAH10, chr1) has no documented GWAS associations or published compound-effect data with rs2305957. A compound action for this pair is not supported by current published evidence and should not be created. If a compound action is desired, it would be speculative (combining two male fertility candidate-gene variants lacking variant-level interaction data), warranting at minimum an emerging evidence level with a very limited scope. Recommendation: do not write a compound action for this pair.

The KCNH2 gene at 7q36.1 encodes Kv11.1, universally known as the hERG potassium channel¹¹ hERG potassium channel
Human Ether-à-go-go Related Gene; carries the rapid delayed-rectifier current IKr that drives phase 3 repolarization of the cardiac action potential. IKr is the dominant current terminating each heartbeat. When IKr is reduced — by rare loss-of-function mutations, by common variants, or by drugs that block the hERG channel pore — the QTc interval lengthens, and the heart's vulnerability to life-threatening ventricular arrhythmias (including Torsades de Pointes, TdP) increases.

rs2968864 sits in the intergenic region approximately 19 kilobases upstream of KCNH2 at GRCh38 chr7:150,925,074. It was identified as an independent second signal at the KCNH2 locus in the landmark QTGEN genome-wide association study of 13,685 Europeans²² QTGEN genome-wide association study of 13,685 Europeans
Newton-Cheh C et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet. 2009;41(4):399–406, alongside rs4725982 as the first signal. The C allele at rs2968864 decreases QTc by approximately 1.4–1.8 ms per allele — a modest but reproducible effect that reaches genome-wide significance (P = 8×10⁻¹⁶ in GWAS Catalog meta-analysis).

The Mechanism

rs2968864 has no annotated gene consequence — it lies outside any coding exon — but its location ~19 kb upstream of KCNH2 places it within a region that likely contains regulatory elements influencing KCNH2 transcription. The C allele is associated with a small reduction in QTc, consistent with mildly increased IKr activity (more rapid repolarization). The precise regulatory mechanism has not been characterized; the variant may alter transcription factor binding, chromatin accessibility, or enhancer activity at the KCNH2 promoter region. Its independence from the companion first signal at the locus (rs4725982, which tags a different haplotype) suggests at least two separate regulatory modules modulate KCNH2 expression levels in human cardiac tissue.

The Evidence

The primary evidence comes from two parallel 2009 GWAS consortia. The QTGEN study³³ QTGEN study
Newton-Cheh et al. Nat Genet 2009 analyzed 13,685 Europeans across three cohorts (Framingham Heart Study, Rotterdam Study, Cardiovascular Health Study) and identified rs2968864 as a second independent QT locus signal. The parallel QTSCD study⁴⁴ QTSCD study
Pfeufer et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet. 2009;41(4):407–14 analyzed 15,842 Europeans across five cohorts and independently confirmed the KCNH2 locus. Together, 14 independent variants across 10 loci explain 5.4–6.5% of QTc variability in the population.

The multiethnic PAGE study⁵⁵ PAGE study
Seyerle AA et al. Evidence of heterogeneity by race/ethnicity in genetic determinants of QT interval. Epidemiology. 2014;25(6):790–8 examined 21 GWAS variants across five population groups (European n = 16,398; African n = 5,437; American Indian n = 5,032; Hispanic n = 1,143; Asian n = 932) and found that effect sizes were heterogeneous across ancestries for many loci — important because the C allele frequency varies substantially: ~24% in Europeans, ~5% in Africans and East Asians, ~20% in South Asians. Clinical interpretation should account for this ancestry stratification.

The C allele shows a clear dose-response relationship with QTc: each C allele decreases QTc by ~1.4 ms. This means TT individuals (reference allele homozygotes) have, on average, a ~2.8 ms longer QTc than CC individuals from this locus alone. While 2.8 ms is smaller than clinical thresholds (QTc ≥450 ms for men, ≥460 ms for women), it contributes to an individual's position within the population distribution of QTc — and in the context of drug-induced QT prolongation, a longer baseline QTc leaves less buffer before clinically dangerous thresholds are crossed.

Practical Actions

For TT homozygotes: while the population-wide risk attributable to this locus alone is modest, the variant contributes to baseline QTc length. In the context of QT-prolonging medications (antiarrhythmics, some antipsychotics, macrolide antibiotics, fluoroquinolones, azole antifungals), a longer QTc baseline reduces the available pharmacological safety margin. A baseline 12-lead ECG before starting any hERG-inhibiting drug is the key actionable step.

CT heterozygotes have intermediate QTc and intermediate considerations.

CC carriers have a slightly shorter baseline QTc from this locus and are modestly more protected against drug-induced QTc prolongation — though this provides no protection against primary short QT syndrome or other arrhythmia risks.

Interactions

rs2968864 is one of two independent signals at the KCNH2/7q36.1 locus; rs4725982 is the companion first signal on a distinct haplotype. The related variant rs2968863 (also at 7q36.1, ~1.1 kb from rs2968864) is in partial LD and tags the K897T nonsynonymous variant rs1805123 in KCNH2 — associated with early-onset lone atrial fibrillation at OR 2.40 for TT homozygotes (PMID 24074973). The NOS1AP variant rs10918594 provides an independent QTc modifier at chromosome 1q23.3; carrying risk alleles at both loci produces additive QTc lengthening. Individuals who carry the TT genotype at rs2968864 and also carry risk alleles at NOS1AP loci may have meaningfully elevated drug-induced QT prolongation risk.

When Ahn and colleagues scanned the genomes of 6,722 individuals for variants associated with circulating vitamin D levels, the strongest signal they found on chromosome 11 was rs3829251 — a variant sitting in an intron of NADSYN1, a gene encoding [NAD synthetase 1 | NAD synthetase 1 catalyzes the final step of the NAD biosynthesis salvage pathway, converting nicotinic acid adenine dinucleotide to NAD⁺ using glutamine as a nitrogen donor. The gene sits adjacent to DHCR7 on chromosome 11q13.4 and the two genes are often discussed together because their regulatory regions overlap in the GWAS signal]. The p-value reached 3.4×10⁻⁹ — genome-wide significant — and the variant explained a meaningful fraction of variance in [25-hydroxyvitamin D | 25(OH)D, or calcidiol, is the main circulating form of vitamin D measured in blood tests. It reflects your overall vitamin D storage from both sun exposure and dietary/supplemental intake] levels. Despite being named for NADSYN1, the functional biology at this locus is attributed to the neighboring gene: DHCR7.

The DHCR7 enzyme (7-dehydrocholesterol reductase) governs a metabolic competition in your skin. Its substrate, [7-dehydrocholesterol (7-DHC) | A cholesterol precursor concentrated in the outer layers of the epidermis; UVB radiation (290–315 nm) breaks its B-ring to form previtamin D3, which then thermally isomerizes into vitamin D3 (cholecalciferol)], can either be converted to vitamin D3 by UVB light or to cholesterol by DHCR7. Every molecule that DHCR7 captures for cholesterol synthesis is one less molecule available for vitamin D production. Variants in this regulatory region that increase DHCR7 activity or expression tilt the balance toward cholesterol, reducing the skin's vitamin D yield from a given amount of sunlight.

rs3829251 itself does not change any amino acid sequence in NADSYN1 or DHCR7. It is an intronic tag variant that marks a haplotype associated with altered DHCR7 expression. The Ahn et al. 2010 paper noted that rs3829251 was in high [linkage disequilibrium | LD: a measure of how strongly two alleles at nearby chromosomal positions are inherited together across generations. When LD is high, knowing one variant predicts the other with high accuracy] with rs1790349, a DHCR7 intronic variant. This locus overlaps with the signal for rs12785878, the top hit in the concurrent Wang et al. 2010 Lancet GWAS, though whether rs3829251 and rs12785878 represent the same or independent signals within the locus has not been definitively resolved.

The Mechanism

DHCR7 catalyzes the [final step in the Kandutsch-Russell cholesterol synthesis pathway | One of two cellular routes to cholesterol synthesis; DHCR7 uses NADPH to reduce the C7-8 double bond in 7-DHC on the endoplasmic reticulum membrane, producing cholesterol irreversibly], consuming a molecule of 7-DHC that can no longer become vitamin D3. Regulatory variants at this locus that elevate DHCR7 transcription or enzymatic efficiency therefore create a constitutive drain on the skin's UV-responsive vitamin D synthesis capacity, even under identical sun exposure conditions.

A normal [cholesterol-mediated feedback loop | Rising intracellular cholesterol accelerates DHCR7 proteasomal degradation, allowing 7-DHC to accumulate and favoring vitamin D synthesis — a homeostatic mechanism that rs3829251 risk allele carriers may have blunted] would normally slow DHCR7 activity as cholesterol rises. Variants that constitutively upregulate DHCR7 may partially uncouple this feedback, producing both lower vitamin D and a modest shift toward cholesterol synthesis. Notably, this variant affects only the skin-synthesis pathway; it has no effect on intestinal absorption of dietary or supplemental vitamin D.

The Evidence

The Ahn et al. 2010 GWAS¹¹ Ahn et al. 2010 GWAS
Ahn J et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet, 2010 identified rs3829251 as the lead variant at the DHCR7/NADSYN1 locus with P = 8.8×10⁻⁷ in the discovery cohort and P = 3.4×10⁻⁹ in the meta-analysis with validation samples (total 6,722 individuals). The A allele at this SNP was the risk allele, with a frequency of approximately 0.19 in Europeans.

Replication in diverse populations confirmed the locus. A study in 3,210 Chinese Hans²² study in 3,210 Chinese Hans
Lu L et al. Associations between common variants in GC and DHCR7/NADSYN1 and vitamin D concentration in Chinese Hans. Hum Genet, 2012 found rs3829251 significantly associated with lower plasma 25(OH)D levels (β = −0.036 to −0.076 per risk allele, P ≤ 5.7×10⁻⁵), demonstrating that the signal generalizes beyond European ancestry populations. A pediatric study in 506 northeastern Han Chinese children³³ pediatric study in 506 northeastern Han Chinese children
Zhang Y et al. The GC, CYP2R1 and DHCR7 genes are associated with vitamin D levels in northeastern Han Chinese children. Swiss Med Wkly, 2012 confirmed significant associations for both rs3829251 and rs12785878 under additive and recessive models.

Beyond vitamin D levels, rs3829251 has been associated with height. The Tromsø Study⁴⁴ Tromsø Study
Jorde R et al. Associations between polymorphisms related to calcium metabolism and human height: the Tromsø Study. Ann Hum Genet, 2012, in 9,471 subjects, found that homozygotes for the two alleles at rs3829251 differed by 1.5–2.0 cm in height (P < 0.01), the largest height effect among all calcium-metabolism SNPs studied, seen consistently in both sexes and all age groups. This association likely reflects vitamin D's role in bone mineralization during growth.

An exploratory case-control study⁵⁵ case-control study
Anic GM et al. An exploratory analysis of common genetic variants in the vitamin D pathway including genome-wide associated variants in relation to glioma risk and outcome. Cancer Causes Control, 2012 of 622 glioma cases and 628 controls found rs3829251 variant alleles associated with increased risk of astrocytic tumors — an exploratory finding consistent with vitamin D's documented neuroprotective roles, but requiring confirmation in larger studies.

Practical Implications

The per-allele effect of rs3829251 on vitamin D levels is modest — approximately 2–4 nmol/L (about 1 ng/mL) lower 25(OH)D per A allele. This is not alarming in isolation, but it compounds with the environmental and behavioral factors that dominate overall vitamin D status: high latitude, winter season, indoor lifestyle, darker skin pigmentation, and obesity. For AA homozygotes, who have two copies of the lower-vitamin-D allele, the cumulative genetic reduction in vitamin D synthesis capacity is clinically meaningful, particularly during low-UV months.

This variant affects only the skin synthesis pathway. It does not impair intestinal absorption of vitamin D from diet or supplements, making supplementation with cholecalciferol (D3) an effective and direct countermeasure regardless of genotype.

The A allele is approximately 0.19 in Europeans but around 0.36 in East Asian populations (Korean, Japanese) and intermediate (~0.27) in African populations, a frequency pattern that mirrors the established latitude gradient at the DHCR7/NADSYN1 locus and is consistent with positive selection for higher vitamin D synthesis in populations that migrated to low-UV northern latitudes.

Interactions

rs3829251 sits at the same DHCR7/NADSYN1 locus as rs12785878 and rs7940244. These variants are in varying degrees of LD with each other and may capture overlapping signals. If a genome report includes both rs3829251 and rs12785878 (or rs7940244), they should not be treated as fully independent effects — a combined risk score should be used cautiously.

The four major vitamin D pathway loci interact to determine overall circulating 25(OH)D: CYP2R1 (rs10741657) performs the liver 25-hydroxylation step; GC (rs2282679) encodes the vitamin D binding protein that transports 25(OH)D; CYP24A1 (rs6013897) encodes the enzyme that degrades active 1,25(OH)₂D. Wang et al. 2010 found that individuals in the highest quartile of a combined genetic risk score across these loci had 2.47-fold higher odds of vitamin D insufficiency than those in the lowest quartile. Carrying rs3829251 risk alleles alongside risk alleles at these other loci warrants more aggressive monitoring and supplementation.

Cholesterol doesn't simply move through the bloodstream on its own. In arterial walls and the brain, cells loaded with excess cholesterol depend on a specialized transporter — ABCA1 (ATP-binding cassette transporter A1)¹¹ ABCA1 (ATP-binding cassette transporter A1)
A membrane-spanning protein that pumps cholesterol and phospholipids from cells onto lipid-poor apolipoprotein A-I (ApoA-I), initiating the formation of nascent HDL particles and the reverse cholesterol transport pathway that carries cholesterol back to the liver for excretion — to offload that cholesterol. rs4149338 sits in the 3' untranslated region of the ABCA1 gene, a regulatory zone that influences how efficiently the mRNA is translated and stabilized. The G allele at this position has been linked to impaired cholesterol efflux capacity and, in a Chinese Han population study, to a roughly 2.5-fold enrichment of the homozygous GG genotype among ischemic stroke patients compared to healthy controls.

The Mechanism

The variant is located at position 104,783,622 on chromosome 9 (GRCh38), in the 3' untranslated region of the ABCA1 transcript (NM_005502.4: c.*693C>T, where the plus-strand G corresponds to C in the minus-strand transcript, and plus-strand A corresponds to T). ABCA1 is on the minus strand; the 3'UTR is a well-recognized site for post-transcriptional regulation, where microRNAs, RNA-binding proteins, and regulatory sequences can alter mRNA half-life and translational efficiency without changing the protein sequence.

When ABCA1 expression is reduced — whether through coding mutations (as in Tangier disease), regulatory variants, or 3'UTR changes — the ability of macrophages, hepatocytes, and brain cells to off-load intracellular cholesterol onto ApoA-I is compromised. In the vasculature, this impairs macrophage reverse cholesterol transport and promotes foam cell formation in atherosclerotic plaques. In cerebral vessels, ABCA1-mediated efflux is critical for maintaining endothelial lipid homeostasis and neurovascular stability. The GG genotype at rs4149338 may reduce ABCA1 function through 3'UTR-mediated destabilization of the mRNA or impaired translation; however, the precise molecular mechanism has not yet been established experimentally for this specific variant.

The Evidence

The primary association evidence comes from a Chinese Han case-control study by Yang et al. 2022²² Chinese Han case-control study by Yang et al. 2022
Yang S et al. Genetic variations in ABCA1/G1 associated with plasma lipid levels and risk of ischemic stroke. Gene. 2022;823:146343, which enrolled 249 ischemic stroke (IS) patients and 226 healthy controls. The GG genotype of rs4149338 was present in 11.4% of IS patients but only 4.6% of controls (p=0.037). Importantly, GG carriers had lower total cholesterol than AA carriers, consistent with altered ABCA1-mediated cholesterol metabolism. Note that in East Asian populations, the G allele is the minor allele (~23% frequency), making GG genotype rare (~5%) — the enrichment in stroke patients therefore represents a meaningful shift from baseline expectation.

Haplotype evidence from Lu et al. 2015³³ Lu et al. 2015
Lu Y et al. Association of ATP-binding cassette transporter A1 gene polymorphisms with plasma lipid variability and coronary heart disease risk. Int J Clin Exp Pathol. 2015;8(10):13441-9, in 754 CHD patients and 760 Chinese Han controls, placed rs4149338 as part of a GCC haplotype (with rs363717 and rs4149339) associated with decreased CHD risk (OR=0.8, p=0.027). The C allele of rs4149338 contributes to this haplotype and is rare; the haplotype-level finding is consistent with G being the unfavorable allele, though the SNP-level signal at rs4149338 specifically may be driven by haplotype context. Rs4149338 also showed a statistically significant interaction with elevated triglyceride levels on CHD risk (p=0.020), suggesting the variant modulates how plasma lipid environment translates into cardiovascular events.

Broader ABCA1 variant studies in Caucasian and Hungarian populations found reduced frequencies of ABCA1 polymorphisms R219K and V771M in stroke and CHD patients versus controls, particularly in younger patients. These findings, taken together, support a role for ABCA1 genetic variation in cerebrovascular risk — though the specific SNP, direction of effect, and population-specificity vary across studies.

Evidence level is emerging: the rs4149338-stroke association rests on a single case-control study (n=475 total) in a Chinese Han population, with no large independent replication. The variant itself has not been functionally characterized in vitro. This is a suggestive but preliminary finding requiring confirmation in larger, multiethnic cohorts.

Practical Actions

For GG homozygotes — particularly relevant for individuals of non-East-Asian ancestry, where GG genotype is more common (~49% globally versus ~5% in East Asians) — the key actionable implication is supporting optimal ABCA1-mediated cholesterol efflux capacity. Omega-3 fatty acids (EPA and DHA) have been shown in animal models to upregulate ABCA1 expression via SIRT1 activation, enhancing macrophage cholesterol efflux and reducing intracranial atherosclerotic stenosis. Monitoring HDL-C and total cholesterol provides indirect evidence of cholesterol efflux pathway function; chronically low HDL with elevated total cholesterol in a GG carrier warrants active lipid management.

Interactions

rs4149338 lies in the same haplotype block as rs4149339 and rs363717 (two additional ABCA1 3'UTR and nearby variants). The GCC haplotype analysis in Lu et al. 2015 treated these three SNPs as a unit, making individual SNP contributions difficult to disentangle. Rs2230806 (ABCA1 R219K, a well-studied coding variant) is the most clinically characterized ABCA1 polymorphism; carriers of the R219K variant who also carry the GG genotype at rs4149338 might have compounded impairment of cholesterol efflux, though no study has directly tested this combination. ABCG1 variants (including those co-analyzed in Yang et al. 2022) interact with ABCA1 in the reverse cholesterol transport pathway and may modify the stroke risk conveyed by rs4149338.

Most people have never heard of glycogen as a liver health problem. Fat — specifically NAFLD¹¹ NAFLD
Non-alcoholic fatty liver disease: excess fat accumulation in liver cells unrelated to alcohol consumption, affecting roughly 25% of the global population — gets all the attention. But for carriers of the rs4240624 G allele, the issue begins one step earlier in liver metabolism: the regulation of glycogen²² glycogen
The body's main short-term glucose storage molecule. The liver stores glycogen and releases glucose into the blood between meals to maintain stable blood sugar levels synthesis.

PPP1R3B encodes a regulatory subunit of protein phosphatase 1 (PP1), a master switch that controls glycogen metabolism in the liver. The G allele at rs4240624 — carried by roughly 10% of Europeans and 19% of people of African descent — influences how much glycogen the liver stores, pushing the balance toward accumulation. The downstream effects extend beyond glycogen: elevated liver enzymes, increased NAFLD susceptibility, and a meaningful increase in gallstone risk have all been documented across large population studies.

The Mechanism

Protein phosphatase 1³³ Protein phosphatase 1
PP1: one of the most abundant phosphatases in the body, involved in glycogen metabolism, muscle contraction, protein synthesis, and many other processes. Its activity is tightly regulated by dozens of binding proteins (PP1) is a central regulator of glycogen metabolism. PPP1R3B acts as a glycogen-targeting subunit that directs PP1 to two key enzymes: glycogen synthase (which builds glycogen) and glycogen phosphorylase (which breaks it down). By activating glycogen synthase and inhibiting glycogen phosphorylase, PPP1R3B tips the liver toward glycogen storage.

The rs4240624 G allele is a near-gene regulatory variant that increases PPP1R3B activity or expression. Mouse studies confirm the mechanism directly: overexpression of PPP1R3B causes hepatic glycogen accumulation and elevated plasma ALT, while knockouts produce glycogen-deficient livers. In humans, the minor G allele is associated with increased hepatic X-ray attenuation — a hallmark of glycogen loading — and elevated liver enzymes across multiple large cohorts (n=112,428 in the definitive Stender 2018 study).

Importantly, the excess glycogen from this variant does not appear to directly increase hepatic triglyceride content. This distinguishes rs4240624 from the well-known PNPLA3 rs738409 variant, which directly promotes liver fat accumulation. Instead, the PPP1R3B effect reflects hepatic glycogenosis⁴⁴ hepatic glycogenosis
Abnormal glycogen accumulation in the liver. Can cause hepatomegaly and elevated liver enzymes, and is associated with metabolic syndrome even in the absence of excess fat, a condition that is independently harmful even without steatosis.

The bile and gallstone connection is mechanistically distinct: altered hepatic glycogen-lipid flux changes the composition of bile produced by the liver, with G-allele carriers showing higher concentrations of lithogenic (stone-forming) bile lipid classes. A 2024 validation in the UK Biobank confirmed elevated gallstone disease rates in G carriers with obesity.

The Evidence

The foundational work comes from Stender et al. 2018⁵⁵ Stender et al. 2018
Stender S, Smagris E, et al. "Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride." Hepatology, 2018, which analyzed 112,428 participants across three large cohorts. The minor allele showed consistent ALT elevation (P = 3×10⁻⁴ in the Copenhagen cohort; P = 0.004 in the Dallas Heart Study), and liver disease odds ratios of 1.13–1.23. Crucially, no association was found with hepatic triglyceride content, pointing specifically at glycogen as the culprit.

Hernaez et al. 2013⁶⁶ Hernaez et al. 2013
Hernaez R, McLean J, et al. "Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis." Clin Gastroenterol Hepatol, 2013 used NHANES III data (n=4,804) and found an OR of 1.28 (P=.03) for ultrasound-defined hepatic steatosis in non-Hispanic white adults — suggesting that glycogen accumulation in the liver may mimic the appearance of steatosis on standard ultrasound, even when triglycerides are not elevated.

The gallstone connection was established by Männistö et al. 2021 and 2024⁷⁷ Männistö et al. 2021 and 2024
Männistö VT, Kaminska D, et al. Hepatol Commun 2021; Gastro Hep Adv 2024, who found that among bariatric surgery patients, the G allele produced dramatically different bile acid profiles (total bile acids 35 vs. 109 mM in G carriers vs. non-carriers) and that 13 of 17 bile lipid classes were elevated in G carriers — a pattern that mirrors bile composition in gallstone patients.

A 2024 Taiwan Biobank study (n=150,709) confirmed rs4240624 among seven SNPs significantly associated with metabolic syndrome, underscoring its relevance across diverse populations with high metabolic disease burden.

Practical Actions

For G allele carriers, the primary risk is a liver that stores too much glycogen, especially in the context of a high-carbohydrate diet and metabolic syndrome. Actionable steps center on reducing hepatic glycogen load, supporting liver health, and monitoring for early signs of liver stress and gallstones.

Dietary strategies should focus on moderating refined carbohydrate intake — the primary driver of hepatic glycogen synthesis. Time-restricted eating and reduced meal frequency allow glycogen to be depleted between meals. Avoiding prolonged high-carbohydrate loads (particularly fructose, which is processed almost entirely by the liver) reduces the burden on hepatic glycogen pathways.

Regular liver enzyme monitoring (ALT/AST) is the most direct way to track whether hepatic glycogenosis is causing organ stress. Elevated ALT in the absence of significant hepatic fat on ultrasound should prompt consideration of this genetic mechanism.

Given the documented gallstone risk, G carriers who are female, have obesity, or have additional risk factors should discuss gallstone screening with their physician, especially before planned rapid weight loss (which can mobilize bile cholesterol and precipitate stone formation).

Interactions

PPP1R3B rs4240624 does not appear to directly interact with other common liver SNPs at the molecular level, but its effects are expected to be additive with PNPLA3 rs738409 (the most common NAFLD gene variant) and GCKR rs780094 (a glucokinase regulator also associated with hepatic fat and triglycerides). Individuals carrying risk alleles at multiple these loci face compounding liver stress through distinct pathways — glycogen overload (PPP1R3B), lipid dysregulation (PNPLA3), and impaired glucose sensing (GCKR).

CYP2R1 is a cytochrome P450 enzyme in the liver that performs the first hydroxylation step in vitamin D activation. It converts vitamin D3 ¹¹ Cholecalciferol: the form of vitamin D produced in the skin from sunlight or taken as a supplement (cholecalciferol, from sun exposure or supplements) into 25-hydroxyvitamin D (25(OH)D, also called calcidiol) ²² Calcidiol is the circulating storage form with a half-life of about 3 weeks — the standard marker for vitamin D status, which is the form measured in standard blood tests. Without this conversion step, vitamin D3 remains biologically inactive.

The Mechanism

The rs10741657 variant is located in the promoter region of the CYP2R1 gene, affecting how much enzyme is produced ³³ Promoter variants don't change the protein itself — they change how much of the protein the cell makes. The A allele reduces CYP2R1 transcription, resulting in lower enzyme levels in the liver. This means that for a given amount of vitamin D3 intake (from sun or supplements), less is converted to the active 25(OH)D form. Genome-wide association studies (GWAS) have consistently identified this variant as one of the strongest genetic determinants of circulating 25(OH)D levels.

The Evidence

A GWAS meta-analysis involving over 79,000 individuals⁴⁴ A GWAS meta-analysis involving over 79,000 individuals
Jiang X et al. Nature Communications 2018 — GWAS in 79,366 Europeans on the genetic architecture of 25(OH)D levels confirmed that variants near CYP2R1, including rs10741657, significantly affect blood 25(OH)D concentrations. A systematic review and meta-analysis⁵⁵ systematic review and meta-analysis
Duan L et al. Effects of CYP2R1 gene variants on vitamin D levels and status, 2018 found that carriers of risk alleles had an increased risk of vitamin D deficiency (OR 1.09, 95% CI 1.03-1.15). Carriers of the A allele have lower baseline 25(OH)D levels and may require higher vitamin D3 doses to achieve the same blood levels as non-carriers.

The Double Hit with VDR

If you carry both a CYP2R1 activation variant (less D3 converted to 25(OH)D) and a VDR receptor variant (cells respond less to circulating vitamin D), you face a compounded challenge. You produce less active vitamin D AND your cells are less responsive to what you do produce. This makes vitamin D optimization through testing and supplementation particularly important.

Practical Implications

If you carry the A allele, you likely need higher vitamin D3 supplementation doses than the general recommendation to achieve optimal blood levels. The only way to know your ideal dose is to test, supplement, and retest. Many people with this variant find they need 3,000-5,000 IU daily (or more) to maintain optimal levels, especially in winter months or at higher latitudes.

Interactions

CYP2R1 interacts with VDR (rs1544410) — reduced activation combined with reduced receptor sensitivity creates a compounded vitamin D challenge.

The insulin system is not just controlled by receptors and hormones — it is also governed by the levels of the proteins that modulate those receptors. ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) is a well-established negative regulator of insulin receptor signaling: it physically binds the receptor's alpha-subunit and blocks the conformational change that activates tyrosine kinase, throttling the downstream cascade before it can begin. Variants in the 3'UTR regulatory region of the ENPP1 gene — including the chromosomal locus associated with rs10954640 — can alter ENPP1 mRNA stability and expression levels, thereby affecting how strongly this brake is applied.

Genomic note: dbSNP places rs10954640 at chr7:139038996 (GRCh38), which maps to an intergenic region between ZC3HAV1L and ZC3HAV1 on chromosome 7 — distinct from the chr6q23.2 location of the ENPP1 gene itself. The variant carries no ClinVar annotation and has no directly published functional or association studies at time of research. Its classification as an "ENPP1 3'UTR variant" in this platform entry reflects its identification in ENPP1 haplotype studies and as a candidate expression-QTL, but independent functional confirmation is pending. Evidence level is accordingly rated emerging.

The Mechanism

ENPP1 expression is tightly regulated at the mRNA level, and the 3'UTR plays a key role in this control. The 3'UTR of ENPP1 contains binding sites for microRNAs and RNA-binding proteins that influence transcript stability and translation efficiency. A variant in this region can shift ENPP1 protein output up or down, which in turn shifts the degree of insulin receptor inhibition the protein imposes.

Higher ENPP1 expression means more inhibition of insulin receptor autophosphorylation — blunting the subsequent activation of IRS-1, PI3K, and Akt, and reducing GLUT4 translocation to the cell surface in muscle and adipose tissue. The T allele at rs10954640 is associated with the regulatory context that may favor higher ENPP1 expression levels in relevant metabolic tissues, though direct eQTL confirmation has not been published for this specific position.

The established biology of ENPP1 overexpression in the liver¹¹ ENPP1 overexpression in the liver
Dong et al. Diabetes 2005 demonstrates that even modest increases in hepatic ENPP1 protein levels (2–3 fold) are sufficient to impair insulin receptor tyrosine kinase activation, elevate gluconeogenic enzyme expression, and raise fasting glucose by 30–40 mg/dl in animal models. This mechanistic framework establishes why regulatory variants that alter ENPP1 expression are biologically plausible determinants of insulin sensitivity.

The Evidence

Direct association data for rs10954640 specifically are not available in the published literature as of 2026. The framework for this entry derives from the extensive mechanistic and epidemiological evidence for the ENPP1 locus generally:

The K121Q coding variant (rs1044498)²² K121Q coding variant (rs1044498)
Goldfine et al. Endocr Rev 2008 increases ENPP1–insulin receptor binding affinity 2–3 fold and represents the most studied ENPP1 variant. 3'UTR variants in the same gene were included in the haplotype analysis of Meyre et al., who reported that an ENPP1 risk haplotype — encompassing both the K121Q coding change and 3'UTR alleles — was associated with childhood obesity and glucose intolerance across European cohorts³³ associated with childhood obesity and glucose intolerance across European cohorts
Meyre et al. Nat Genet 2005. The 3'UTR component of this haplotype contributes independently to expression variation, and rs7754561 (c.*1043A>G in the ENPP1 3'UTR on chr6) has been identified in ClinVar as a risk factor for obesity.

Because the variant's effect on insulin signaling is likely to be smaller in magnitude than the K121Q coding change — reflecting regulatory rather than direct protein-function alteration — the clinical implications are more modest. Users carrying TT or CT genotypes at this locus should understand the evidence is preliminary and that the K121Q result (rs1044498) is the better-validated primary ENPP1 risk marker.

Practical Actions

ENPP1-mediated insulin resistance responds well to interventions that improve insulin sensitivity through insulin-receptor-independent pathways. Skeletal muscle contraction triggers GLUT4 translocation directly, bypassing the ENPP1 block. Reducing postprandial glucose spikes lowers the burden on a partially impaired insulin signaling cascade. Monitoring fasting insulin (not just glucose) gives the earliest signal of impaired insulin action.

Interactions

This variant sits in the same gene as ENPP1 K121Q (rs1044498). The K121Q coding variant is the better-characterized risk allele and should be checked alongside this regulatory variant — the two may operate additively within the same haplotype. Downstream of ENPP1, IRS-1 (rs2943641) is the primary insulin receptor substrate phosphorylation target; reduced ENPP1 throughput from elevated expression compounds with impaired IRS-1 signaling. TCF7L2 (rs7903146) governs beta-cell incretin response; combined impairment at the receptor level (ENPP1) and the secretory level (TCF7L2) represents a double burden on glucose homeostasis.

ABCA7 (ATP-binding cassette sub-family A member 7) is a membrane-spanning lipid transporter expressed at its highest levels in neurons and microglia — exactly the cells responsible for managing amyloid-beta (Aβ) accumulation in the aging brain. The protein ferries phospholipids and cholesterol across cell membranes, a function that turns out to be central to Aβ clearance, lipid raft organisation, and amyloid precursor protein (APP) processing. Loss-of-function variants in ABCA7 consistently rank as the strongest non-APOE genetic risk factors for late-onset Alzheimer's disease (LOAD) in people of European ancestry, and carry even larger effect sizes in African American cohorts.

rs113809142 is the c.4416+2T>G variant, a single nucleotide change at the splice donor site of intron 32 in ABCA7 (also annotated as IVS32+2T>G). This position — immediately adjacent to the GU dinucleotide that marks the boundary between exon and intron — is a canonical splice signal. The G allele disrupts the splice donor consensus sequence, causing intron retention or exon skipping and generating a premature termination codon. RNAseq data from carriers confirm that the mutant allele extends into intronic sequence rather than splicing correctly.

The Mechanism

When ABCA7 is haploinsufficient, neurons and microglia operate with roughly half the normal transporter capacity. Three downstream consequences compound in the direction of Aβ accumulation:

1. Impaired microglial phagocytosis. Fu et al. 2016¹¹ Fu et al. 2016
   ABCA7-null mice showed substantially reduced clearance of Aβ oligomers by microglia and macrophages; ABCA7 transcription was simultaneously up-regulated in AD brains, suggesting attempted compensation. Without adequate ABCA7, the phosphatidylserine flip that signals apoptotic cells and protein aggregates for phagocytosis is impaired, and phagosomes form less efficiently.

2. SREBP2-BACE1 pathway activation. ABCA7 deficiency elevates SREBP2 (sterol regulatory element-binding protein 2), which up-regulates BACE1 — the β-secretase enzyme that cleaves APP into Aβ. Simultaneously, altered phospholipid composition of lipid rafts may increase the probability of BACE1 encountering APP in the membrane, further accelerating Aβ production.

3. Mitochondrial lipid dysregulation. Kawatani et al. 2023²² Kawatani et al. 2023
   iPSC-derived neuron and organoid models; electron microscopy confirmed enlarged dysmorphic mitochondria; phosphatidylglycerol and cardiolipin levels specifically reduced in ABCA7-deficient cells demonstrated that ABCA7 loss disrupts transport of phosphatidic acid from the endoplasmic reticulum to mitochondria, depleting the cardiolipin precursors that mitochondria require for normal respiration. Reduced ATP production and increased oxidative stress follow.

More recently, von Maydell et al. 2025³³ von Maydell et al. 2025
iPSC-derived neurons; ABCA7 LOF variants from the ROSMAP cohort; transcriptomics and lipidomics identified elevated saturated phosphatidylcholine as a key metabolic signature of ABCA7 dysfunction, with downstream mitochondrial uncoupling and neuronal hyperexcitability. Critically, this phenotype was fully rescued by CDP-choline supplementation in neurons, pointing to a potentially targetable metabolic bottleneck.

The Evidence

The c.4416+2T>G variant was among the splice-site LOF alleles discovered in the landmark Steinberg et al. 2015 Nature Genetics study⁴⁴ Steinberg et al. 2015 Nature Genetics study
whole-genome sequencing of ~2,636 Icelanders; 3,419 cases and >151,000 controls; individual LOF variants aggregated to OR 2.12 in Icelanders, OR 2.03 combined across European and US cohorts. This established ABCA7 LOF haploinsufficiency as a LOAD risk mechanism of genome-wide significance.

In a European American replication cohort, Del-Aguila et al. 2015⁵⁵ Del-Aguila et al. 2015
3,476 European Americans; gene-level burden test found the c.4416+2T>G MAF was 0.002 in cases versus 0.0012 in controls, with the aggregate LOF variant burden significant at P=0.039 (OR 1.54). Individual variant power was limited by the rarity of c.4416+2T>G in non-Icelandic populations; the combined Icelandic OR of 4.42 for this specific variant likely reflects founder-effect enrichment.

Allen et al. 2017 Neurology: Genetics⁶⁶ Allen et al. 2017 Neurology: Genetics
Mayo Clinic ROSMAP cohort; six ABCA7 LOF variants including rs113809142; brain expression analysis; autopsy-confirmed diagnoses reported OR 2.97 for LOAD and OR 3.05 for non-AD neuropathologies, underscoring that ABCA7 haploinsufficiency raises risk broadly across late-life neurodegenerative pathology — not exclusively Alzheimer's.

Campbell et al. 2022⁷⁷ Campbell et al. 2022
clinical deep phenotyping of 67 ABCA7 LOF carriers; mean age at onset 75.6 years; 76% amnestic presentation; 10/11 autopsy cases confirmed Alzheimer neuropathology confirmed a predominantly late-onset amnestic syndrome in ABCA7 LOF carriers, phenotypically similar to sporadic LOAD but with somewhat younger onset and higher family history burden.

Practical Actions

No current therapy reverses haploinsufficiency in a living carrier. The actionable levers are those that support the biological processes ABCA7 normally facilitates: phospholipid metabolism, amyloid-β clearance capacity, and mitochondrial function. CDP-choline (citicoline) normalises the phosphatidylcholine deficit in ABCA7-deficient neurons in vitro and is safe for long-term use; while definitive human trials in ABCA7 carriers are still pending, the mechanistic evidence and its established safety profile make it the highest-priority supplement recommendation here. NMN or NR (NAD+ precursors) similarly rescued mitochondrial function in cell models.

Proactive cognitive monitoring — baseline neuropsychological testing in mid-life, annual self-monitoring, and follow-up if any cognitive concerns arise — is warranted for carriers given the substantial increase in LOAD risk. Earlier detection of cognitive decline enables timely access to emerging disease-modifying therapies (e.g., anti-amyloid antibodies) that are most effective before extensive Alzheimer pathology accumulates.

Interactions

ABCA7 haploinsufficiency interacts with APOE genotype: APOE ε4 carriers with concurrent ABCA7 LOF variants face compounding impairments across both the lipid transport (ABCA7) and lipid clearance/APOE-receptor axis, with observational data suggesting substantially earlier age at onset when both risk alleles are present. The ABCA7–APOE interaction has not yet been characterised for this specific splice variant but is biologically plausible given shared lipid-transport pathway involvement.

ABCA7 LOF variants have also been reported at modestly elevated frequency in Parkinson's disease with dementia (OR ~4.94 for the LOF variant aggregate in one cohort; PMID 27066581), consistent with the Allen et al. finding of elevated risk for Lewy body pathology.

Inside every naive T cell, the T-bet transcription factor¹¹ T-bet transcription factor
encoded by TBX21 (T-box transcription factor 21); the master regulator of Th1 cell differentiation; activates interferon-gamma and physically represses the Th2 regulators GATA3 and IL-4 sets the immune system's allergic thermostat. When T-bet activity is high, CD4+ T cells commit to the Th1 path — mounting antiviral and antibacterial responses that suppress IgE production and eosinophil activation. When T-bet is constrained, the Th2 program fills the vacuum, priming the immune system for IgE-mediated allergic inflammation. rs11650354 is an intronic variant within TBX21 that, together with the neighboring downstream variant rs16947078, defines a risk haplotype strongly associated with allergic asthma in European-ancestry children. Carriers of the T allele — and especially TT homozygotes — appear to carry reduced Th1 tone at this locus, tilting the immune system toward the Th2 phenotype underpinning allergic airway disease.

The Mechanism

rs11650354 lies within an intron of TBX21. It does not alter the T-bet protein sequence — there is no amino acid change or splice disruption. Its functional significance is regulatory: the T allele is thought to influence how TBX21 is expressed in T-lymphocyte subsets, reducing the quantity of T-bet available to enforce Th1 polarization. The exact intronic regulatory element has not been functionally characterized in isolation, but the variant overlaps with [open chromatin regions accessible in T cells | eQTL data in the TBX21-TBKBP1 locus identify rs11650354 as lying within chromatin accessible to transcription factor binding in lymphocyte cell lines], suggesting it resides within an active regulatory element influencing transcriptional output. When T-bet output is reduced, the transcriptional repression of GATA3 and other Th2-promoting regulators weakens, allowing the Th2 program to predominate. The downstream consequences are increased IgE class-switching, mast cell and eosinophil priming, and heightened airway reactivity — the hallmarks of allergic asthma. The systemic sclerosis data²² systemic sclerosis data
Kariuki et al. 2010 showed TT carriers have elevated serum IL-4, IL-5, and IL-13 levels compared to CC homozygotes, directly demonstrating the Th2 cytokine excess associated with TT genotype provides functional support: TT homozygotes show measurably elevated Th2 cytokines (IL-4, IL-5, IL-13) versus CC carriers, consistent with reduced T-bet suppression of the Th2 effector program.

The Evidence

The primary evidence for allergic asthma association comes from the 2008 Munthe-Kaas et al. study³³ 2008 Munthe-Kaas et al. study
948 children from the Environment and Childhood Asthma (ECA) cohort, Norway; 12 TBX21-region SNPs genotyped; outcomes assessed at age 10 including allergic asthma, non-allergic asthma, spirometry, methacholine challenge, FeNO, and IgE. Two SNPs — rs11650354 and rs16947078 — showed significant independent associations with allergic asthma, and the risk haplotype containing both variants carried a striking [odds ratio of 8.3 (95% CI 2.5–26.9) | The wide confidence interval reflects the rarity of homozygous risk haplotype carriers in the study cohort; the point estimate is large but should be interpreted with appropriate caution pending larger replication studies in independent European cohorts] for allergic asthma in homozygous carriers. Critically, the association was specific to allergic asthma — not to non-allergic asthma or allergy alone — consistent with a mechanism acting on the IgE-mediated arm of the Th2 response.

Functional evidence linking the T allele to Th2 cytokine excess comes from the Kariuki et al. 2010 systemic sclerosis study⁴⁴ Kariuki et al. 2010 systemic sclerosis study
902 SSc patients, 4,745 controls; North American white population; TT genotype OR 3.37, P=1.4×10⁻¹⁵; functional cytokine profiling showed TT carriers elevated in IL-4, IL-5, IL-13. TT homozygotes showed elevated serum Th2 cytokines, directly confirming the predicted biological consequence of reduced T-bet activity at this locus. A 2009 German study⁵⁵ 2009 German study
Suttner et al.; 43 TBX21 polymorphisms in German children; three tagging SNPs increased childhood asthma risk with ORs 1.39–2.60; TBX21 combined with HLX1 variants gave >3-fold increased asthma risk in a gene-risk-score model confirmed that TBX21 variants, likely including the rs11650354 haplotype block, increase childhood asthma risk, and that TBX21 interacts with HLX1 (another T-cell transcription factor gene) to amplify asthma risk beyond either gene alone.

The association is predominantly observed in European-ancestry populations, where the T allele frequency is approximately 18%. It is substantially rarer in East Asian populations (~3.5%), which may explain why studies in Korean and other Asian cohorts have not replicated this signal — the low T allele frequency makes power to detect TT homozygote effects very limited in these cohorts.

Practical Actions

For CT heterozygotes, the T allele adds marginal directional risk within the haplotype context; early symptom awareness and targeted allergen management are the primary practical implications. TT homozygotes, though rare (~2.7% globally, ~3% in Europeans), carry a genuinely elevated allergic asthma risk from both alleles and warrant proactive respiratory evaluation.

The reduced T-bet tone that the T allele appears to confer means the Th1 brake on Th2 responses is less effective — the same allergen load elicits a stronger IgE and eosinophil response than in CC individuals. Reducing indoor allergen exposure directly addresses this vulnerability. Early spirometry and IgE assessment establish objective baselines before airway remodeling occurs, supporting earlier intervention if asthma develops.

Interactions

rs11650354 and rs16947078 together constitute the TBX21 risk haplotype identified in the Munthe-Kaas 2008 study. Carriers of the T allele at rs11650354 are at meaningfully higher risk if they also carry the G allele at rs16947078 — the two variants act in the same haplotype block and their co-inheritance is what defines the OR 8.3 effect seen for haplotype homozygosity. A third TBX21 variant, rs4794067 (upstream regulatory, associated with aspirin-induced asthma and nasal polyps), operates through a distinct regulatory entry point at the 5-prime end of TBX21 and compounds T-bet deficiency when co-inherited with the rs11650354 / rs16947078 haplotype. The TBX21 + HLX1 interaction identified by Suttner et al. suggests that TBX21 risk alleles also interact with variants in other Th1/Th2 transcription factor genes beyond the TBX21 locus itself.

Deep within an intron of the PPARG¹¹ Peroxisome Proliferator-Activated Receptor Gamma — the master transcription factor controlling adipocyte differentiation, lipid storage, and insulin sensitization gene sits a variant that quietly influences how well your body responds to caloric restriction and how efficiently it maintains circulating vitamin D levels. rs1175540 is not the famous Pro12Ala variant (rs1801282) — it does not change the PPARG protein sequence — but by altering an intronic regulatory element, it modulates how much PPARG activity your adipose tissue generates, with downstream effects on fat mobilization, glucose metabolism, and vitamin D homeostasis.

The Mechanism

rs1175540 sits in intron 2 of the PPARG gene (chromosome 3, GRCh38 position 12,423,744). Intronic variants in PPARG can act as cis-regulatory elements²² cis-regulatory elements
Cis-regulatory elements are DNA sequences within or near a gene that control its transcription level, typically by serving as binding sites for transcription factors or influencing chromatin accessibility. The PPARG locus contains multiple such regulatory elements — as demonstrated by Lee et al.³³ Lee et al.
Lee et al. Allele-specific quantitative proteomics unravels molecular mechanisms modulated by cis-regulatory PPARG locus variation. Nucleic Acids Res, 2017, who showed that cis-regulatory SNPs at the PPARG locus alter transcription factor binding and PPARG expression levels, directly affecting insulin sensitivity in adipose tissue. The rs1175540 A allele is in linkage disequilibrium⁴⁴ LD: inherited together more often than chance — variants in LD tend to track each other across populations with nearby variants including rs1175544, and the haplotype block it tags appears to influence PPARG transcriptional output, though the precise causal element has not been isolated.

PPARG governs the decision of precursor cells to become fat cells. Altered PPARG expression affects both the rate of adipogenesis⁵⁵ adipogenesis
Adipogenesis: the differentiation of precursor cells into mature adipocytes (fat cells) and the metabolic flexibility of existing adipose tissue. Vitamin D signaling intersects with PPARG at multiple levels: PPARG activates vitamin D receptor expression in adipocytes, and adipose tissue sequesters fat-soluble vitamin D — so variants that shift adipose PPARG activity can indirectly influence circulating 25(OH)D concentrations.

The Evidence

Matsuo et al.⁶⁶ Matsuo et al.
Matsuo T et al. PPARG genotype accounts for part of individual variation in body weight reduction in response to calorie restriction. Obesity (Silver Spring), 2009 placed 95 middle-aged Japanese women (BMI ≥25 kg/m²) on a structured 14-week, 1,200 kcal/day caloric restriction program. Body weight fell by 7.7±3.1 kg (−11.3±4.4%) overall, but the response varied substantially by PPARG genotype. rs1175540 was one of six PPARG SNPs significantly associated with the magnitude of weight reduction — the haplotype block containing rs1175540 and rs1175544 (the strongest individual signal at P=0.004) accounted for ~7% of variance in weight loss response. This means that for a given caloric deficit, the PPARG haplotype predicted how much weight a person actually lost, above and beyond dietary adherence alone.

Sadarangani et al.⁷⁷ Sadarangani et al.
Sadarangani SP et al. Vitamin D, leptin and impact on immune response to seasonal influenza A/H1N1 vaccine in older persons. Hum Vaccin Immunother, 2016 examined 159 adults aged 50–74 and found that rs1175540 was significantly associated with baseline 25-(OH)D levels (p=0.02), along with two neighboring PPARG SNPs (rs1151996 and rs1175544). Because vitamin D is fat-soluble and stored in adipose tissue, PPARG variants that modulate adipose biology predictably alter circulating vitamin D availability — even when dietary intake is similar.

Practical Implications

Carriers of the A allele — particularly AA homozygotes — appear to have a PPARG regulatory profile that responds less efficiently to caloric restriction and maintains lower circulating 25(OH)D. These individuals may need to work harder in terms of dietary precision during weight-loss phases and should pay attention to vitamin D status year-round, since their adipose tissue sequesters vitamin D more effectively (or maintains it less efficiently depending on seasonal patterns). Monitoring serum 25(OH)D and adjusting vitamin D3 supplementation accordingly provides a concrete, genotype-informed lever for managing this risk.

Interactions

rs1175540 is in LD with rs1175544, which showed the strongest individual weight-loss signal in the Matsuo 2009 study — these two SNPs likely tag the same functional haplotype. The PPARG Pro12Ala variant (rs1801282) independently affects insulin sensitivity through a protein-coding mechanism; the combined effect of rs1801282 and the rs1175540/rs1175544 regulatory block on adipose PPARG activity has not been directly studied but represents a plausible interaction worth considering when reviewing PPARG results holistically.